Effect of Diltiazem on Coronary Artery Ectasia

Status Completed

Clinical Trial Summary

Coronary artery ectasia (CAE) has been defined as localized or diffuse dilatation of epicardial coronary arteries more than 1.5 fold of adjacent normal segments. Isolated CAE constitutes minor portion of the total CAE cases, with an incidence of 0.1% to 0.79% in which coronary artery stenosis or severe valvular heart diseases are not present. CAE represents not only an anatomical variant but also a clinical constellation of coronary artery disease (CAD) like association with myocardial ischemia and acute coronary syndromes. Patients with CAE without significant coronary narrowing may still present with angina pectoris, positive stress tests, or acute coronary syndromes. Impaired epicardial and microvascular perfusion were demonstrated in ectatic coronary arteries.

Myocardial blush grading (MBG) technique has been utilized in various conditions such as acute myocardial infarction, coronary artery ectasia, syndrome X and idiopathic dilated cardiomyopathy to evaluate myocardial perfusion.

There is still no consensus for management of CAE. Previously improvement of coronary flow has been demonstrated by mibefradil in patients with slow coronary flow. A new trial is needed to explore the effect of calcium channel blockers (CCB) in isolated CAE. Diltiazem improves myocardial perfusion by blocking calcium channels in coronary arteries. This agent has been widely used in coronary catheter labs to prevent and treat no-reflow.

The current study with prospective design was therefore set up to assess whether epicardial flow and tissue level perfusion would be improved by diltiazem in myocardial regions subtended by the ectatic coronary arteries among patients with isolated CAE.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Coronary Artery Ectasia

Clinical Trial Details

NCT number	NCT02024919
Study type	Interventional
Source	Ankara University
Contact
Status	Completed
Phase	N/A
Start date	June 2012
Completion date	May 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05233124` - Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia	Phase 2
Recruiting	`NCT05713201` - Outcomes After PCI of the Aneurysmatic Right Coronary Artery
Recruiting	`NCT04265989` - A New Classification and Interventional Therapy for Coronary Artery Ectasia	N/A
Recruiting	`NCT00548457` - Endothelial Function in Patients With Ectatic Compared to Normal Coronary Arteries	N/A
Not yet recruiting	`NCT05213429` - Jordanian Coronary Artery Ectasia Registry
Completed	`NCT05410678` - Safety And Efficacy Results of Percutaneous Renal Stent Implantation in Ectatic and Aneurysmatic Coronary Arteries	Phase 4
Recruiting	`NCT02818127` - Assessment Of Total Coronary Circulation Time Using TIMI Frame Count Method (TCCT-TIMI)	N/A
Recruiting	`NCT02831153` - Evaluation of Emotional Status and Coronary Flow Characteristics by TIMI Frame Count Method	N/A
Recruiting	`NCT06057987` - Coronary Artery Ectasia Database - Poland
Not yet recruiting	`NCT05692115` - Ischemia and Inflammatory Markers Among Patients With Coronary Artery Ectasia
Recruiting	`NCT05106530` - Arrhythmogenic Risk Assessment in Coronary Artery Ectasia Patients
Not yet recruiting	`NCT05718531` - Coronary Artery Ectasia, Efficacy of Various Anti Thrombotic Regimens.	Phase 3
Completed	`NCT06220682` - Endothelial NO Synthase Polymorphic Gene in Coronary Artery Dilation Disease